Weight regain after stopping GLP-1s: the employer’s problem

In the STEP-10 trial, patients who stopped semaglutide regained over 40% of their lost weight within 28 weeks. In SURMOUNT-4, more than half of weight loss with tirzepatide rebounded within 52 weeks of stopping. A 2025 meta-analysis in eClinicalMedicine found that discontinuing GLP-1 therapy causes an average weight regain of 9.69 kg in patients on semaglutide or tirzepatide. For employers offering GLP-1 coverage, this is not a theoretical concern.

Why employees stop GLP-1s

Research from Prime Therapeutics shows only 1 in 12 members remain on GLP-1 treatment after three years. A 2025 JAMA Network Open study of 125,474 patients found 64.8% of those without type 2 diabetes discontinued within their first year. The reasons cluster around side effects, cost and coverage changes, feeling “done” after reaching a goal weight, and insufficient behavioral support.

The employer’s problem: three financial consequences

Drug spend without lasting outcomes. If an employee uses GLP-1s for 18 months, loses 15% of body weight, stops, and regains within a year, the employer has spent $13,000–$16,000 in pharmacy costs with no lasting clinical benefit.

Downstream claims don’t improve. The business case for GLP-1 coverage rests partly on downstream savings from reduced obesity-related claims. These savings materialize over years. If employees are cycling on and off medication, the downstream claims trajectory doesn’t improve in the way actuarial models predict.

Reinitiation creates a second spend cycle. The JAMA study found 36.3% of patients without type 2 diabetes who discontinued reinitiated a GLP-1 within a year. For employers, that’s a recognizable pattern — and one that a better program design can interrupt.

What actually prevents weight regain

The evidence on post-GLP-1 weight maintenance points to two variables: behavioral foundation and structured tapering. Employees who have worked with a behavioral coach — using ACT or CBT — are meaningfully better equipped for the transition off medication. Structured tapering (gradual dose reduction rather than abrupt cessation) produces significantly less weight regain than stopping abruptly.

Embla’s TRIM study data shows that participants who complete the behavioral program maintain weight stability after tapering to zero. 78.5% of 2,694 participants successfully tapered or ceased GLP-1 medication. The protocol begins tapering at month 16 over 12 weeks.

The maintenance phase

A dedicated post-taper maintenance program addresses relapse risk directly — continued coaching focused on habit reinforcement, regular check-ins, access to clinical escalation if weight regain triggers clinical thresholds. The Embla Embrace program is designed for exactly this phase, protecting the employer’s investment in the active treatment phase by reducing the probability of costly reinitiation.

The questions to ask every vendor

Ask: what happens when an employee completes the program? Do you have a structured tapering protocol and outcomes data? What does post-cessation support look like? What percentage of your participants reinitiate GLP-1s within 12 months? A vendor who can’t answer these is, implicitly, a vendor whose program ends when medication ends.

Embla includes a structured taper protocol, ACT/CBT behavioral coaching, and a post-treatment maintenance program. 78.5% of participants taper or stop GLP-1s entirely. See the outcomes →